

# Pulse Duration Settings in Subthalamic Stimulation for Parkinson's Disease

Frank Steigerwald, MD,<sup>1</sup> Lars Timmermann, MD,<sup>2</sup> Andrea Kühn, MD,<sup>3</sup> Alfons Schnitzler, MD,<sup>4</sup> Martin M. Reich, MD,<sup>1</sup> Anna Dalal Kirsch, MD,<sup>1</sup> Michael Thomas Barbe, MD,<sup>2</sup> Veerle Visser-Vandewalle, MD,<sup>2</sup> Julius Hübl, MD,<sup>3</sup> Christoph van Riesen, MD,<sup>3</sup> Stefan Jun Groiss, MD,<sup>4</sup> Alexia-Sabine Moldovan, MD,<sup>4</sup> Sherry Lin, PhD,<sup>5</sup> Stephen Carcieri, PhD,<sup>5</sup> Ljubomir Manola, PhD,<sup>6</sup> and Jens Volkmann, MD<sup>1\*</sup>

<sup>1</sup>Department of Neurology, Universitätsklinikum Würzburg, Würzburg, Germany <sup>2</sup>Departments of Neurology and Functional & Stereotactic Neurosurgery, Universitätsklinikum Köln, Köln, Germany <sup>3</sup>Department of Neurology, Charité, University Medicine Berlin, Germany <sup>4</sup>Department of Neurology, Universitätsklinikum Düsseldorf, Düsseldorf, Germany <sup>5</sup>Boston Scientific Neuromodulation, Valencia, California, USA <sup>6</sup>Boston Scientific Neuromodulation, Diegem, Belgium

## ABSTRACT

**Background:** Stimulation parameters in deep brain stimulation (DBS) of the subthalamic nucleus for Parkinson's disease (PD) are rarely tested in double-blind

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

\*Corresponding author: Prof Dr Jens Volkmann, Department of Neurology, University Clinic of Würzburg, Josef-Schneider-Str. 11, D-97080 Würzburg, Germany; volkmann\_j@ukw.de

**Funding agencies:** Boston Scientific Neuromodulation financed the study, contributed to the design of the study protocol, monitored the conduct of the study, and assisted with technical support during data collection (SC, LM). Boston Scientific employed statisticians (SL) who were responsible for data management and performed statistical analysis, but all data were provided to JV, LT, AK, and AS, who had full responsibility for the integrity of the data, the accuracy of the analysis, and the interpretation of the results. Boston Scientific contributed to early drafts of the manuscript (SC), but the final draft of the manuscript was written by JV, and reviewed by LT, AK, and AS, who are responsible for the content of the manuscript and the decision to submit for publication. Boston Scientific also paid for the services of a medical writer to edit, format and prepare the manuscript for submission.

**Relevant conflicts of interests/financial disclosures:** L.T. reports grants, personal fees and non-financial support from Medtronic, grants, personal fees, and nonfinancial support from Boston Scientific, personal fees and nonfinancial support from SAPIENS, grants, personal fees and nonfinancial support from St. Jude Medical during the conduct of the study. S.L., S.C., and L.M. report employment with Boston Scientific. J.V. reports grants and personal fees from Boston Scientific during the conduct of the study. F.S., M.M.R., A.D.K., M.T.B., V.V.-V., J.H., C.R., S.J.G., and A.-S.M. have nothing to disclose.

**Received:** 6 March 2017; **Revised:** 16 October 2017; **Accepted:** 18 October 2017

Published online 22 November 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27238

conditions. Evidence-based recommendations on optimal stimulator settings are needed. Results from the CUSTOM-DBS study are reported, comparing 2 pulse durations.

**Methods:** A total of 15 patients were programmed using a pulse width of 30  $\mu$ s (test) or 60  $\mu$ s (control). Efficacy and side-effect thresholds and unified PD rating scale (UPDRS) III were measured in meds-off (primary outcome). The therapeutic window was the difference between patients' efficacy and side effect thresholds.

**Results:** The therapeutic window was significantly larger at 30  $\mu$ s than 60  $\mu$ s ( $P = .0009$ ) and the efficacy (UPDRS III score) was noninferior ( $P = .00008$ ).

**Interpretation:** Subthalamic neurostimulation at 30  $\mu$ s versus 60  $\mu$ s pulse width is equally effective on PD motor signs, is more energy efficient, and has less likelihood of stimulation-related side effects. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

**Key Words:** Deep brain stimulation; Parkinson's disease; pulse width; stimulation parameters; subthalamic

The efficacy and side effect profile of deep brain stimulation (DBS) critically depends on the electrical activation of specific neural elements within a small brain volume.<sup>1</sup> Factors that determine the volume of tissue activated (eg, electrode position, electrical field shaping effects of contact selection, polarity, and current amplitude) affect the stimulation outcome. Neurostimulation effects also depend on the temporal characteristics of the stimulus waveform, and changes in pulse duration may impact the selectivity of neural activation within a given stimulation volume.<sup>2</sup>

The CUSTOM-DBS study was designed to address the need for an evidence-based update of DBS programming guidelines,<sup>1</sup> including the expanded parameter space of novel DBS devices. The primary outcome was the use of shorter pulse widths than 60  $\mu$ s to expand the window between thresholds for therapeutic effects and side effects, without compromising efficacy, and for which there is a well-understood and plausible mechanism of action.<sup>3</sup> An exploratory outcome was the impact of current fractionalization among adjacent contacts using multiple independent current control. Here, we report results on the pulse duration programming change between 30 and 60  $\mu$ s in an acute, double-blind comparison. The results of current steering are included in the Supplementary Appendix.

## Methods Participants

PD patients bilaterally implanted with a Vercise DBS system (Boston Scientific, Valencia, California) in the STN for at least 3 months were included at 4 German

centers. All patients had a Unified Parkinson's Disease Rating Scale (UPDRS) subset III score of  $\geq 30$  in the preoperative meds-off state, and  $\geq 30\%$  symptom reduction in the meds-off state (UPDRS III score) by DBS. To ensure sufficient rigidity to reliably measure a threshold, a meds-off rigidity score  $\geq 2$  was required in the evaluated arm (UPDRS III). Patients were excluded if severe tremor would interfere with measurements, defined as meds-off resting and/or action tremor score  $\geq 3$  on the evaluated side (UPDRS III). Patient demographics are shown in Supplementary Table 1.

All sites obtained ethics committee approval. Written informed consent was given by all patients before study inclusion. The study is registered with ClinicalTrials.gov (NCT01896115).

### Randomization and Masking

Test conditions were administered in random order with masking of patients and the examiner to treatment assignment. Random permutations of the treatment sequence, stratified by site with a block size of 4, were pregenerated along with a set of mutually distinct identification codes. To mask the randomization assignment, each site only received the codes, each sealed within a numbered envelope to be opened sequentially as patients enrolled into the study. The non-blinded programmer controlled the pulse width and electrode settings according to the randomization sequence matched to the code using a computer positioned out of the examiner's sight.

### Procedures

Primary data collection occurred in a single programming visit. Patients arrived in the practically defined meds-off state (at least 12-hour drug withdrawal). The clinical DBS effect was washed out by turning the device off for at least 1 hour. Testing was started when the patient and examiner agreed that a representative off-state was reached. DBS was then turned back on contralateral to the clinically more affected side of the body. To evaluate pulse-width effects, cathodic stimulation was delivered through the best single therapeutic electrode (monopolar against generator case), fixed at 130 Hz; pulse width was randomly assigned to either test (30  $\mu$ s) or control (60  $\mu$ s) settings. At each setting, amplitude was gradually increased until a side effect threshold was measured (defined as the minimum amplitude for any side effect persisting after 2 minutes of stimulation). Rigidity was evaluated 0.1 mA below the side effect threshold to assess the maximum rigidity control possible at that setting. The efficacy threshold was defined as the amplitude at which rigidity reoccurred by gradually decreasing the stimulation in steps of 0.1 mA.

Efficacy was measured in 2 ways after at least 15 minutes of continuous stimulation at the previously

determined efficacy threshold for each setting: UPDRS III evaluation (including lateralized scores calculated by summing items for left and right sides separately), and an objective, quantitative assessment of tremor and bradykinesia using a finger-worn motion sensor (Kinesia ProView, Great Lakes Neurotechnologies, Cleveland, Ohio). In the latter assessment, patients performed 3 tasks while wearing a motion sensor on the index fingertip: rest tremor assessment, finger-tapping task, and rapidly alternating-movement task. The study design is summarized in Fig 1.

Efficiency of neurostimulation was calculated as the total charge delivered per pulse ( $Q = I * \text{pulse width}$ ) at the efficacy threshold.

### Statistical Analysis

The coprimary endpoints of this study were (1) superiority of the therapeutic window size and (2) noninferiority of stimulation efficacy (UPDRS III) on the most affected side of contralateral DBS with 30  $\mu$ s compared to 60  $\mu$ s pulse width. The 2 endpoints were each assessed using a 1-sided paired *t* test at an alpha level of 0.025, applying the Bonferroni correction to preserve the family-wise error rate. A margin of 5 points, representing the minimal clinically relevant difference,<sup>4</sup> was established as the noninferiority margin for UPDRS III.


Sample size calculations suggested that the first coprimary endpoint (superiority of therapeutic window size) could be met after 16 participants, whereas the noninferiority endpoint would require 40 enrolled participants. Therefore an interim analysis was planned after enrollment of the first 16 patients and confirmed that both coprimary endpoints could be met at this stage. Therefore, the study could be discontinued, as per protocol, after the enrollment of 16 participants.

## Results

### Therapeutic Efficacy and Side Effect Thresholds

Of 16 enrolled participants, 1 did not tolerate reprogramming and withdrew before any data could be collected. Therefore, 15 patients completed the study.

For these 15 participants, stimulation at 30  $\mu$ s resulted in a significantly larger therapeutic window than 60  $\mu$ s (mean 3.82 vs 2.32 mA;  $P = .0009$ ; Fig 2A). The most common side effect thresholds were those for muscle contractions and dysarthria related to pyramidal tract activation (Fig. 2B). Efficacy at the rigidity threshold at 30  $\mu$ s was noninferior to 60  $\mu$ s as measured by total UPDRS motor score (mean 31.9 vs 31.3;  $P = .00008$ ) or by lateralized motor score for the evaluated side (18.8 vs 18.1;  $P = .00051$ ). Noninferiority of the stimulation efficacy at 30  $\mu$ s was further confirmed by kinematic measures of rest tremor,



**FIG. 1.** Schematic of the CUSTOM-DBS study, a multicenter, double-blind, randomized controlled trial. At the programming visit, the therapeutic window was first measured in a randomized, double-blind assessment at four different program settings. Double-blind UPDRS III and exploratory quantitative assessments (Kinesia assessments of rest tremor, finger tapping, and rapidly alternating movement tasks; Kinesia ProView, Great Lakes Neurotechnologies) were then taken at the efficacy threshold for rigidity for each setting. In addition to test and control pulse width settings, current steering settings were also tested as exploratory endpoints. Stimulation was activated on the best therapeutic contact as identified by clinical practice and programmed according to the figure. [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

finger-tapping, or rapidly alternating movements (Supplementary Fig. 1).

### Efficiency of Neurostimulation

As predicted by the strength-duration relationship<sup>5</sup> efficacy and side effect thresholds were higher at a pulse width of 30  $\mu$ s (3.05 mA and 6.87 mA, respectively) when compared with 60  $\mu$ s (2.31 mA and 4.63 mA). However, neurostimulation efficiency is not measured by the threshold amplitude, but by the required amount of charge—a function of both amplitude and pulse width.<sup>6</sup> The total charge delivered per pulse at efficacy threshold was lower at 30  $\mu$ s pulse width, indicating that short pulse width stimulation is more efficient at exciting the neural elements responsible for therapeutic benefit (Supplementary Fig. 2;  $-34\%$  difference; mean charge per pulse = 91.6 nC/pulse at 30  $\mu$ s, 138.4 nC/pulse at 60  $\mu$ s).


### Discussion

In DBS therapy, amplitude, pulse width, and frequency settings are adjusted in each patient individually, starting with standard values, to achieve the maximum reduction of clinical signs with minimal side effects and energy consumption.<sup>6</sup> We have

demonstrated here that standard programming settings used in STN-DBS for PD may not be optimal.

When tested in a double-blind, acute challenge, a shorter pulse width of 30  $\mu$ s was superior to the standard 60  $\mu$ s in terms of minimizing the likelihood of stimulation-related side effects while maintaining the same therapeutic efficacy at a lower energy cost. Modelling data suggest that the mechanism of stimulation at short pulse duration may be best explained by focusing on excitation of smaller diameter axons near the electrode and a steeper falloff for activation of thick myelinated axons with increasing radius of current spread.<sup>3</sup> This would reduce the likelihood of inadvertent stimulation of pyramidal tract fibers causing muscle contractions or dysarthria, the most frequently observed signs, when testing adverse effect thresholds in this study.

It should be noted that 30  $\mu$ s itself may not be optimal. The programming time limitations prevented an exhaustive comparison of pulse width settings, and even shorter pulse widths might further expand the therapeutic window. In DBS, chronaxie for tremor suppression was previously estimated at approximately 65 to 75  $\mu$ s,<sup>7</sup> indicating that shorter pulse widths can excite the target fibers at safe current amplitudes. We selected 30  $\mu$ s as the test pulse width



**FIG. 2.** Coprimary endpoints. **(A)** Superiority of the therapeutic window size (left) and noninferiority of UPDRS III (right) at a short-pulse width. Error bars represent  $\pm 1$  standard error. **(B)** Side effect observed at threshold during the therapeutic measurement. The most common side effects were dysarthria and muscle twitch related to pyramidal tract activation. [Color figure can be viewed at [wileyonlinelibrary.com](http://wileyonlinelibrary.com)]

based on a small pilot study<sup>3</sup> because there was a steep increase of side effect thresholds at 20  $\mu$ s often exceeding an arbitrarily chosen upper testing limit of 10 mA. In clinical practice, many patients might benefit from reducing pulse widths from conventionally used 60  $\mu$ s or more to 30 to 50  $\mu$ s, in cases where side effects do occur.

We were unable to explore other settings that may be superior. The number of combinations of pulse width, frequency, and voltage available within the recommended charge density limit was calculated to be 12,964 in older DBS devices,<sup>6</sup> and since then that number of combinations has only increased with the introduction of additional electrodes, expanded pulse



width range, current steering, and other programmable features of the device. It is not possible to test all settings in a single programming visit, and more studies are needed to define the optimal parameter space for target signs.

Another limitation was the lack of data on efficacy of chronic stimulation at a short pulse width. The participants were only exposed to each stimulation setting for a short time during a single programming visit; it is possible that long-term stimulation would have revealed differences between short and conventional pulse widths that were not apparent during the acute visit. However, the blinded assessment of motor signs (UPDRS III) during an acute stimulation challenge has previously been used as the primary efficacy endpoint in DBS studies<sup>8-10</sup> and reflected the chronic benefit of DBS.

Despite these limitations, few controlled studies are aimed at achieving optimization of DBS programming, and this is the first double-blind assessment of the effect of a shorter pulse width and 1 of only a handful of DBS programming studies that have ever been conducted in a double-blind condition.

In conclusion, stimulation using a shorter than currently recommended pulse width may be more efficient at achieving therapeutic efficacy and less likely to reach a side effect threshold. This may translate into a fundamentally new basic parameter setting for patients with DBS in PD. ■

**Acknowledgments:** Editorial assistance was provided by Deborah Nock (Medical WriteAway, Norwich, UK), funded by Boston Scientific International SA.

## References

1. Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. *Mov Disord* 2006;21(suppl. 14):S284-S289.
2. Volkmann J, Herzog J, Kopper F, Deuschl G. Introduction to the programming of deep brain stimulators. *Mov Disord* 2002; 17(suppl. 3):S181-S187.
3. Reich M, Steigerwald F, Sawalhe A, et al. Short pulse width widens the therapeutic window of subthalamic neurostimulation. *Ann Clin Transl Neurol* 2015;2(4):427-432.
4. Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the Unified Parkinson's Disease Rating Scale. *Mov Disord* 2006;21(8):1200-1207.
5. Ranck J. Which elements are excited in electrical stimulation of mammalian central nervous system? *Brain Res* 1975;98:417-440.
6. Dayal V, Limousin P, Foltynie T. Subthalamic nucleus deep brain stimulation in Parkinson's disease: the effect of varying stimulation parameters. *J Parkinson's Dis* 2017;7:235-245.
7. Holsheimer J, Dijkstra E, Demeulemeester H, Nuttin B. Chronaxie calculated from current-duration and voltage-duration data. *J Neurosci Methods* 2000;97:45-50.
8. Rodriguez-Oroz M, Obeso J, Lang A, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. *Brain* 2005;120(Pt 10):2240-2249.
9. Moro E, Lozano AM, Pollak P, et al. Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. *Mov Disord* 2010;25(5):578-586.

10. Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *N Engl J Med* 2001;345(13):956-963.

## Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's website.

## Short Pulse Width in Subthalamic Stimulation in Parkinson's Disease: a Randomized, Double-Blind Study

Walid Bouthour, MD,<sup>1,2</sup> Jennifer Wegrzyk, PhD,<sup>1</sup> Shahan Momjian, MD,<sup>3</sup> Julie Péron, PhD,<sup>1</sup> Vanessa Fleury, MD,<sup>1</sup> Emilie Tomkova Chaoui,<sup>1</sup> Judit Horvath, MD,<sup>1</sup> Colette Boëx, PhD,<sup>1</sup> Christian Lüscher, MD,<sup>1,2</sup> Pierre R. Burkhard, MD,<sup>1</sup> Paul Krack, MD, PhD,<sup>1</sup> and André Zacharia, MD<sup>1,4\*</sup>

<sup>1</sup>Department of Neurology, Geneva University Hospital, Geneva, Switzerland <sup>2</sup>Department of Basic Neuroscience, University of Geneva, Geneva, Switzerland <sup>3</sup>Department of Neurosurgery, Geneva University Hospital, Geneva, Switzerland <sup>4</sup>Sobell Department of Motor Neuroscience, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK

## Abstract

**Background:** We investigated the acute effect of short pulse widths on the therapeutic window in subthalamic nucleus deep brain stimulation in Parkinson's disease. **Methods:** We assessed 10 PD patients with STN-DBS at a 60- $\mu$ s pulse width. We randomly and double-blindly applied 10- to 50- $\mu$ s pulse widths. The principal outcome was the therapeutic window (difference

\*Correspondence to: Dr. André Zacharia, MD, Movement Disorders Unit, Department of Neurology, Geneva University Hospital, 4, rue Gabrielle-Perret-Gentil, 1211 Genève, Switzerland; andre.zacharia@hcuge.ch

**Relevant conflicts of interest/financial disclosures:** Financial disclosures related to the research covered in this article are Walid Bouthour received onetime travel and accommodation funding from Boston Scientific.

**Funding agencies:** André Zacharia was supported by the Projet Recherches et Développement des Hôpitaux Universitaires de Genève: 2-2015-II and by the Swiss National Science Foundation project P2GEP3\_151597.

**Received:** 27 June 2017; **Revised:** 21 October 2017; **Accepted:** 5 November 2017

**Published online 21 December 2017 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.27265**